Importance of retinoic acid-inducible gene I and of receptor for type I interferon for cellular resistance to infection by Newcastle disease virus

被引:39
作者
Fournier, Philippe [1 ]
Wilden, Holger [1 ]
Schirrmacher, Volker [1 ,2 ]
机构
[1] German Canc Res Ctr, D-69120 Heidelberg, Germany
[2] Ctr Immunol & Oncol IOZK, D-50674 Cologne, Germany
关键词
oncolytic virus; Newcastle disease virus; virus replication; innate cellular response; RIG-I; normal versus tumor cells; cellular toxicity; safety; cellular antiviral response; type I interferon; tumor selectivity; DOUBLE-STRANDED-RNA; RIG-I; NEGATIVE REGULATION; IFN-BETA; CELLS; ACTIVATION; PROTEIN; NDV; INVOLVEMENT; RECOGNITION;
D O I
10.3892/ijo.2011.1222
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Newcastle disease virus (NDV) is an avian paramyxovirus with oncolytic properties which shows promising effects in the treatment of cancer. Anti-cancer effects are due to the virus ability: i) to replicate in and kill tumor cells, leading finally to their selective elimination; and ii) to induce the stimulation of antitumor activities in immune cells. NDV does not harm normal cells and has a high safety profile. In this study, we first report a direct correlation between the degree of cell resistance to NDV infection and the cellular expression of the retinoic acid-inducible gene I (RIG-I) which is a cytosolic viral RNA receptor. RIG-I plays an important role in the recognition of and response to infection by RNA viruses. We also demonstrate that impairment of the interferon (IFN) pathway through deletion of the receptor for type I IFN (IFNR1) in primary macrophages leads to NDV replication. In tumor cells, addition of exogenous IFN-alpha 4 is shown to lead to tumor growth reduction and inhibition of viral replication. Finally, increase of the RIG-I concentration of tumor cells via plasmid transfection is shown to be associated with a stronger resistance to NDV infection. These findings shed new light on the crucial role played by the cytosolic receptor RIG-I and the plasma membrane receptor IFNR1 as key molecules to protect cells against infection by NDV.
引用
收藏
页码:287 / 298
页数:12
相关论文
共 56 条
  • [1] Apoptotic Cells Promote Their Own Clearance and Immune Tolerance through Activation of the Nuclear Receptor LXR
    A-Gonzalez, Noelia
    Bensinger, Steven J.
    Hong, Cynthia
    Beceiro, Susana
    Bradley, Michelle N.
    Zelcer, Noam
    Deniz, Jose
    Ramirez, Cristina
    Diaz, Mercedes
    Gallardo, German
    Ruiz de Galarreta, Carlos
    Salazar, Jon
    Lopez, Felix
    Edwards, Peter
    Parks, John
    Andujar, Miguel
    Tontonoz, Peter
    Castrillo, Antonio
    [J]. IMMUNITY, 2009, 31 (02) : 245 - 258
  • [2] Tissue tropism in the chicken embryo of non-virulent and virulent Newcastle diseases strains that express green fluorescence protein
    Al-Garib, SO
    Gielkens, ALJ
    Gruys, E
    Peeters, BPH
    Koch, G
    [J]. AVIAN PATHOLOGY, 2003, 32 (06) : 591 - 596
  • [3] Alexander DJ, 1988, NEWCASTLE DIS, P1
  • [4] Preferential cytotoxic effect of Newcastle disease virus on lymphoma cells
    BarEli, N
    Giloh, H
    Schlesinger, M
    ZakayRones, Z
    [J]. JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY, 1996, 122 (07) : 409 - 415
  • [5] Biron C.A., 2001, FIELDS VIROLOGY, P321
  • [6] Molecular basis for an attenuated cytoplasmic dsRNA response in human embryonic stem cells
    Chen, Ling-Ling
    Yang, Li
    Carmichael, Gordon G.
    [J]. CELL CYCLE, 2010, 9 (17) : 3552 - 3564
  • [7] mda-5, but not RIG-I, is a common target for paramyxovirus V proteins
    Childs, Kay
    Stock, Nicola
    Ross, Craig
    Andrejeva, Jelena
    Hilton, Louise
    Skinner, Michael
    Randall, Richard
    Goodbourn, Stephen
    [J]. VIROLOGY, 2007, 359 (01) : 190 - 200
  • [8] MTH-68/H oncolytic viral treatment in human high-grade gliomas
    Csatary, LK
    Gosztonyi, G
    Szeberenyi, J
    Fabian, Z
    Liszka, V
    Bodey, B
    Csatary, CM
    [J]. JOURNAL OF NEURO-ONCOLOGY, 2004, 67 (1-2) : 83 - 93
  • [9] Interferons, immunity and cancer immunoediting
    Dunn, Gavin P.
    Koebel, Catherine M.
    Schreiber, Robert D.
    [J]. NATURE REVIEWS IMMUNOLOGY, 2006, 6 (11) : 836 - 848
  • [10] Clinical development directions in oncolytic viral therapy
    Eager, R. M.
    Nemunaitis, J.
    [J]. CANCER GENE THERAPY, 2011, 18 (05) : 305 - 317